Navigation Links
Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
Date:10/25/2010

ST. LOUIS, Oct. 25 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it will release its financial results for the third quarter ended September 30, 2010, on Monday, November 1, 2010 after the close of the market. The Company will host a conference call and webcast on Monday, November 1, 2010 at 4:30 p.m. Eastern Time to discuss the Company's third quarter results and corporate developments.

The dial-in number for the conference call is 1-877-941-9205 for domestic participants and 1-480-629-9835 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 1-800-406-7325 for domestic callers and 1-303-590-3030 for international callers, both using passcode 4377272#. The call will also be available on the Internet live and 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=73566

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
2. Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year
3. Stereotaxis to Present at the JMP Securities Healthcare Conference
4. Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent
5. Stereotaxis to Present at the CL King Best Ideas Conference and the Stifel Nicolaus Healthcare Conference
6. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
7. Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
8. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
9. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
10. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
11. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: ... today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in clinical ... track record, having supported the advancement of several products ... the United States and ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... industry, announced today that Legacy Health is expanding its use of Intrigma’s cloud-based ... a highly successful initial proof of concept. The Portland, Oregon based health system ...
(Date:5/3/2016)... ... 03, 2016 , ... AvePoint, the Microsoft Cloud ... 6 Service Pack (SP) 7, the enterprise-class infrastructure management platform for SharePoint. ... of the platform’s latest features – whether in an on-premises, cloud, or hybrid ...
(Date:5/3/2016)... MD (PRWEB) , ... May 03, 2016 , ... ... line of reusable bags to replace billions of single-use, throw away plastic baggies. The ... devastating our oceans and sea life. , “The LunchSkins mission is all ...
(Date:5/2/2016)... FL (PRWEB) , ... May 03, 2016 , ... ... version of its FDA approved sSOIP telemedicine stethoscope software that enables the stethoscope ... version is called PCP-SSP and works with RNK’s flagship PCP-USB stethoscope. , Remote ...
(Date:5/2/2016)... ... May 02, 2016 , ... As directed by its ... Pennsylvania (HAP) issues its full support to allow certified nurse practitioners (CNP) to practice ... they have worked under such supervision for three years and 3,600 hours. , In ...
Breaking Medicine News(10 mins):